Key terms
About BRIDGEBIO PH 25/31CV 144A
Sector
Health Technology
Industry
Biotechnology
Home page
FIGI
BBG01SJXY4S8
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Related bonds
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.